What is it about?
In patients with STEMI under a pharmaco-invasive strategy, therapy with ticagrelor was associated with a smaller infarct size than clopidogrel.
Featured Image
Why is it important?
In STEMI patients managed with a pharmaco-invasive strategy, receiving optimal medical therapy and timely invasive procedures, those treated with ticagrelor exhibited smaller infarct sizes compared to those receiving clopidogrel, despite having similar pre- and post-reperfusion angiographic coronary characteristics.
Perspectives
Our findings suggest additional benefits from ticagrelor, beyond the potent antiplatelet action, such as improved microcirculation, possibly mediated in part by adenosine.
Francisco Fonseca
Universidade Federal de Sao Paulo
Read the Original
This page is a summary of: Smaller infarct size with ticagrelor vs. clopidogrel in STEMI patients: Insights from cardiac magnetic resonance, PLOS One, October 2025, PLOS,
DOI: 10.1371/journal.pone.0328114.
You can read the full text:
Contributors
The following have contributed to this page
